The concern of generic challenges has long loomed over copyright’s famous drug, PDE5 Inhibitor, sparking questions about the prospects of similar medicinal investments. While first years saw substantial gains, the intellectual property expiration has opened the way for cheaper alternatives, potentially reducing revenue and posing a real danger fo